Quetiapine
Quetiapine is an antipsychotic. Its label indicates it for schizophrenia and for manic episodes in bipolar I disorder. Its boxed warning has two separate parts, and the first concerns a group the medicine is not licensed to treat at all.
Key points
- The label indicates it for the treatment of schizophrenia.
- It is also indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex.
- The boxed warning states that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death, and that quetiapine is not approved for that use.
- The second limb covers suicidal thoughts and behaviours, which antidepressants increased in children, adolescents and young adults in short-term studies.
How it works
Quetiapine is an atypical antipsychotic, used both for psychosis and for mood episodes in bipolar disorder. The breadth of that use is why the boxed warning matters: a medicine reaching across psychiatric conditions is also one that gets considered for behavioural symptoms in dementia, which is exactly the use the warning exists to prevent.
Safety specific to quetiapine
Increased mortality in dementia-related psychosis. The first boxed limb is unambiguous. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death, and quetiapine is not approved for the treatment of patients with dementia-related psychosis.
Those are two statements rather than one. There is a mortality signal, and there is no approval for that use. Both matter for families weighing sedation of an agitated relative with dementia.
Suicidal thoughts and behaviours. The second limb carries the antidepressant warning: antidepressants increased the risk of suicidal thoughts and behaviour in children, adolescents and young adults in short-term studies. The label is equally specific about the boundary of that finding: these studies did not show an increase in patients over age 24, and there was a reduction in risk in patients aged 65 and older.
In patients of all ages started on antidepressant therapy, the label directs close monitoring for worsening and for emergence of suicidal thoughts and behaviours, and advises families and caregivers of the need for close observation and communication with the prescriber.
When to seek urgent care
New or worsening suicidal thinking, or unusual changes in behaviour, need to reach the prescriber promptly rather than at the next scheduled review.